Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | LRAT | O95237 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | GJA1 | P17302 | 1/20 | 0.30 |
| ▸ | GJB2 | P29033 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10820248 | 0.86 | L3MBTL1 (0.40) | L3MBTL1MAPTTSHRSLC2A1MAPK1 | |
| SCHEMBL19859960 | 0.85 | L3MBTL1 (0.36) | L3MBTL1MAPTMEN1LRATTRPV1 | |
| SCHEMBL22652618 | 0.83 | L3MBTL1 (0.34) | L3MBTL1MAPT | |
| SCHEMBL19422849 | 0.82 | L3MBTL1 (0.38) | L3MBTL1MAPTMEN1LRATTRPV1 | |
| SCHEMBL22652633 | 0.81 | L3MBTL1 (0.33) | L3MBTL1MAPT | |
| SCHEMBL31680339 | 0.81 | OGA (0.37) | MEN1LRATTRPV1TSHRHSD17B10 | |
| SCHEMBL12447497 | 0.81 | OGA (0.37) | MEN1LRATTRPV1TSHRHSD17B10 | |
| SCHEMBL14260217 | 0.80 | MEN1 (0.46) | L3MBTL1MEN1LRATTRPV1TSHR | |
| SCHEMBL24205791 | 0.79 | L3MBTL1 (0.44) | L3MBTL1MAPTSLC2A1MAPK1 | |
| SCHEMBL24205805 | 0.79 | L3MBTL1 (0.44) | L3MBTL1MAPTSLC2A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180110866-A1 | POLYMERIC ANTIBIOTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-04-26 | — | — | US | disclosed |
| US-9889204-B2 | Polymeric antibiotics | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110866-A1 | POLYMERIC ANTIBIOTICS | ALG1, TLR3, PGLS | L3MBTL1 2512/4885MAPT 3929/4885MEN1 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.